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follow-up time was 175.5 days (range 19-1402 days). Kaplan-
Meier estimates were used for engraftment, relapse, TRM, OS
and RFS rates with all patients who expired before engraftment
counted as engraftment failures. Patients were also stratiﬁed by
risk status. Results are summarized below. These results dem-
onstrate that HSCT using unrelated PD UCB can be performed
safely with outstanding results in pediatric patients with malig-
nancies.
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SUPERIOR DISEASE-FREE SURVIVAL IN ACUTE MYELOGENOUS LEUKE-
MIA/MYELODYSPLASTIC SYNDROME RECEIVING REDUCED-INTENSITY
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM
UNRELATED DONORS USING FLUDARABINE, BUSULFAN, AND TOTAL
LYMPHOID IRRADIATION
Kato, K.1, Khaled, Y.1, Braun, T.2, Levine, J.E.1, Ferrara, J.L.M.1,
Mineishi, S.1, Gregory, Y.A.1 1Blood and Marrow Stem Cell Trans-
plantation Program, University of Michigan, Ann Arbor, MI; 2Depart-
ment of Biostatistics, School of Public Health, University of Michigan,
Ann Arbor, MI.
Reduced-intensity stem cell transplantation (RIST) from un-
related donors (UD) is shown to be feasible treatment option for
acute myelogenous leukemia/myelodysplastic syndrome (AML/
MDS). Although morbidity and mortality from graft-versus-
host disease (GVHD) may be still signiﬁcant, transplant from
UD may carry more potent graft-versus-leukemia (GVL) effect.
Patients and Method A total of 36 patients (median age: 59
years old, range: 2-69) with AML/MDS were transplanted with
RIST using related and unrelated donors. Patients were condi-
tioned with ﬂudarabine (125mg/m2), intravenous busulfan
(6.4mg/kg), and total lymphoid irradiation (2-4Gy) (Flu/Bu/
TLI). Tacrolimus and methotrexate were given as prophylaxis
for GVHD. Twenty patients underwent RIST in complete
remission (CR), and remaining 16 patients in non-CR. Related
donors (RD) were used in 16 patients (8 in CR and 8 in non-CR
at transplantation), and UD in 20 patients (12 were in CR and
8 in non-CR at transplantation).
Results The median follow-up of survivors was 971 days
(range: 109-1489), while 14 patients relapsed between 16 and
794 days (median 181 days). Overall survival (OS) and disease-
free survival (DFS) at 2 years after RIST were 29.5% and
28.5%, repsectively. The incidence of acute GVHD was rela-
tively low (grade 0: 58%, grade 1: 19%, grade 2: 14%: grade 3-4:
8%). A survival advantage was seen for UD compared to RD
(DFS at 2 years: 42.0% versus 9.2%, log-rank P0.009). The
relapse rate after RIST from RD was 71%, while from UD was
23%. The following factors were analyzed by univariate and
multivariate analyses: age, sex, disease status at transplantation,
source of stem cells (peripheral blood or bone marrow), RD or
UD, number of CD34 positive cells transplanted, and acute
GVHD. In univariate analysis, RD, non-CR at transplant, and
low cell doses transplanted (less than 5  106 /kg of CD34
positive cells), were identiﬁed as poor prognostic factors for
DFS. In multivariate analysis, RD (P0.029), non-CR at trans-
plantation (P0.020), and low cell doses (P0.030) were iden-
tiﬁed as independent risk factors for DFS. Complete donor
chimerism was achieved more consistently by day 100 in trans-
plants from UD than from RD (P0.044).
Conclusion Our observations suggest that RIST using
Flu/Bu/TLI from UD is a feasible transplant option for AML/
MDS patients, with possibly more potent GVL effect than using
RD through early achievement of complete donor chimerism.
Unrelated versus related donors in RIST for AML/MDS
Stem cell source
Acute
GVHD
(grade2-4)
NRM
at 2yr
relapse
at 2yr
2yr
DFS
Unrelated donors
(UD) 25% 32% 23% 42%
Related donors
(RD) 19% 32% 71% 9%
NRM indicates non relapse mortality. NRM and relapse rate are
evaluated by the cumulative incidence using Gray’s method.
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SUPERIOR EFS AND REDUCED TRM IN PATIENTS WITH INT-2 AND
HIGH RISK MDS AND SECONDARY AML AFTER INITIAL CYTOREDUC-
TION WITH 5-AZACYTIDINE
McCarty, J.M.1, Roberts, C.H.1, Candler, K.S.1, Edwards, R.W.1,
Chung, H.M.1, Shickle, L.M.1 1BMT Program, Massey Cancer Center,
VCU Medical Center, Richmond, VA.
Optimized preparative regimens and supportive care have al-
lowed more MDS patients access to potentially curative stem cell
transplantation. Early relapse accounts for up to 30% of advanced
MDS. Leukemia induction chemotherapy prior to transplant re-
duces relapse incidence but with increased TRM. 5-Azacytidine
(5Aza) in advanced MDS may delay disease progression to AML,
has a signiﬁcant response, reduces marrow blast counts, often
within the ﬁrst 2-4 cycles, and is well tolerated. We examined the
use of pre-transplant cytoreduction with 5Aza in Int-2 or High risk
MDS and secondary AML. Patients received at least 4 cycles of
5Aza. Patients with improving marrow blast counts continued on
5Aza to best response(n10), those with greater than 20% blasts
were treated with FLAG(n7), and 5Aza patients with progressive
blast counts crossed over to FLAG(n5). Patients achieving CR/
VGPR proceeded to transplant. 22 patients (median age 49 range
16-68) were followed from the initiation of treatment. With a
median follow up of 535 days (range 36 to 1435), EFS of both 5Aza
and FLAG treated patients was comparable (MS not yet reached)
in contrast to shorter EFS of 5Aza patients crossing over to FLAG
(MS 18 mo). Tests of equality over groups are not signiﬁcant
(Log-Rank p0.1652), although data suggests better early EFS in
the 5Aza alone group. Of the initial 22 patients, 17 underwent
allogeneic transplant (median age 46, range 16-62). The remainder
were ineligible due to refractory disease, infection or comorbidi-
ties. Patients received targeted busulfan-based preparative regi-
mens; 9 received MRD and 8 MUD transplant. With median
follow up of 250 days(range 24-1304), EFS of the 5Aza group is
superior to the FLAG group (MS not yet reached); both are far
superior to the 5Aza to FLAG group(MS 7 mo; Log-Rank
p0.0448). All patients receiving chemotherapy had a higher rate
of early TRM compared with those receiving 5Aza alone. It is
unclear if the inferior EFS of the 5Aza to FLAG group is due to
higher TRM or identiﬁes patients at higher risk for early relapse.
While these cohorts are small, they represent the longest continu-
ing follow up of patients treated with this strategy, and their
survival compares very favorably with historical EFS for MDS.
These early results suggest 5Aza as initial cytoreductive therapy
before transplantation is a strategy worth pursuing in planned
larger multicenter trials to conﬁrm these promising outcomes.
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ADULT PATIENTS WITH MALIGNANCIES TRANSPLANTED WITH
PLASMA DEPLETED CORD BLOOD (PD CB) – A RETROSPECTIVE AU-
DITED ANALYSIS OF 68 PATIENTS
Nademanee, A.1, Graham, M.2, Ballen, K.3, Tan, A.M.4,
Rosenthal, J.1, Karanes, C.1, Eames, G.5, Tan, P.6, Jaing, T.-H.7,
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1City of Hope National Medical Center, Duarte, CA; 2University of
Arizona Medical Center, Tucson, AZ; 3Massachusetts General Hospital,
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gapore; 7Chang Gung Children’s Hospital & University, Linkou, Tai-
wan; 8StemCyte International Cord Blood Center, Arcadia, CA; 9UCLA
School of Public Health, Los Angeles, CA.
Cell dosage is a limiting factor for cord blood transplantation
(CBT), especially for adult patients. Most CB banks practice red
cell depletion (RCD) techniques to save storage space, which incur
signiﬁcant nucleated cell loss after processing. One method to
maximize cell recovery and still reduce volume after processing is
to deplete plasma (PD), but not the red blood cells. Not washing
UCB (NW) after thawing also minimizes cell loss. A third strategy
is to employ double cords. A large racially diverse PD UCB
inventory of over 25,000 units is now available. An audited retro-
spective analysis was performed on all adult patients with malig-
nancies that have available engraftment and/or survival data, with
20 AML, 18 ALL, 12 CML, and 18 patients transplanted for other
malignant indications. Of these, 20 patients had standard risks
(29%), 34 patients (50%) with advanced risks and 14 risk status
unknown (21%). Patients were classiﬁed as adults in two different
ways: by age (16 years and older) and by weight (at least 50kg). By
age, there were 55 patients transplanted with 67 PD UCB units (27
double cords). By weight, there were 62 patients transplanted with
75 PD UCB units (31 double cords). The median age of patients of
the combined group was 29 years old (range 9.6-59); median
weight 62 kg (range 39-112); male 55%. Transplant characteristics
indicated a median # HLA ABDR matches of 4.0; median pre-
freeze TNC dose 2.9  107/kg; median post-thaw TNC dose as
reported by TC 2.5 107/kg; median pre-freeze CD34 dose 0.9
105/kg; transplants outside of U.S. 24%; double unit transplant
47%; non-myeloablative 29%. Fifty-two percent of the trans-
planted UCB were washed post-thaw (W) and 41% were infused
without post-thaw wash (NW), with 7% of the units without
available post-thaw data. Median follow-up time was 111.5 days
(range 2-1263 days). Kaplan-Meier estimates were used for en-
graftment, relapse, TRM, OS and Relapse Free Survival (RFS)
rates with all patients who expired before engraftment counted as
engraftment failures. Patients 16 years or older were also stratiﬁed
by risk status. Results are summarized below. These results dem-
onstrate that HSCT using unrelated PD UCB can be performed
safely and effectively in adult patients with malignancies.
Outcome Summary
ANC500
KM,
median
days
Plt
20K
KM,
median
days
Plt
50K
KM,
median
days
1-Yr
Relapse
KM
100
day &
1-Yr
TRM
KM
1-Yr
OS
KM
1-Yr
RFS
KM
Age
>16 yo
895%,
22 days
819%,
44 days
7110%,
70 days 318%
276%,
427% 417% 387%
Early Risk 8810% 7713% 6315% 2616%
1510%,
2613% 5316% 4815%
Adv Risk 955% 8015% 8115% 3911%
228%,
4411% 339% 339%
Wt
>50 kg
856%.,
24 days
868%,
51 days
739%,
70 days 288%
276%,
417% 437% 427%
ANC 500 - Neutrophil Engraftment, Plt 20K - Platelet 20K
Engraftment, Plt 50K - Platelet 50K Engraftment, TRM -
Transplant Related Mortality, OS - Overall Survival, RFS -
Relapse Free Survival, KM - Kaplan Meier Estimates, Adv -
Advanced, Wt - Weight
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EFFECT ON INTERRUPTION OF CXCR4-CXCL12 AND VLA4-VCAM1
AXES ON MOBILIZATION AND SENSITIZATION OF LEUKEMIA CELLS
AND NORMAL STEM CELLS TO CHEMOTHERAPY
Ramirez, P.A.1, Nervi, B.1, Bridger, G.2, Dipersio, J.F.1 1Washington
University, St. Louis, MO; 2AnorMED, Canada.
Hematopoietic stem cells (HSC) interact with stromal cells, os-
teoblasts and matrix proteins in the hematopoietic niche. This
interaction plays an important role in HSC trafﬁcking, prolifera-
tion and differentiation. Signiﬁcant data support the roles of both
the SDF-1/CXCR4 and the VCAM1-VLA-4 axes in stem cell
homing and mobilization. Little is known regarding the impact of
these ligand-receptor pairs in leukemia cell trafﬁcking. We hy-
pothesize that both CXCR4VLA-4 play important roles in leu-
kemia cell trafﬁcking while also transmitting protective signals
enhancing survival and resistance to chemotherapy and that their
blockade may enhance the sensitivity of AML to chemotherapy.
To evaluate this we developed a model of human APL in which
the PML-RAR
 is “knocked-into” the mouse cathepsin G locus
allowing for expression in the promyelocyte compartment. APL
tumors generated from these CGPR/ mice were transduced with
retroviral contructs containing the Click Beetle Red/eGFP optical
imaging reporter gene for tracking APL cells using biolumines-
cence imaging (BLI). Unlike other AML cell lines tested these
APL cells rapidly migrated to the BM (femurs and spine) by day4
followed by egress to the spleen (11) then to the peripheral blood
and death (18-22). The administration of AMD3100, a CXCR4
antagonist, induced a rapid mobilization of normal HSC and leu-
kemia cells from the BM into peripheral blood (PB). The addition
of AMD3100 1 hour before and 3 hours after either ara-C or
daunorubicin on day 11 resulted in signiﬁcant improvement in
overall survival and decrease in total photon emission compared to
those mice treated with chemotherapy alone.
We have extended these studies using an inhibitor of VLA-4
(AMD15057) and have shown that this molecule directly mobilizes
HSC and APL cells from the BM into the peripheral blood within
minutes and when administered with AMD3100 has a synergistic
effect on both HSC and APL mobilization. Current studies are
aimed at looking at in vitro and in vivo effects of blocking CXCR4
and VLA-4 axes on normal HSC and leukemia cell mobilization
and what effects these events might have on the sensitivity of
normal and leukemic stem cells to chemotherapy and other geno-
toxic stresses.
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BCR/ABL POSITIVITY PRECEDING STEM CELL TRANSPLANTATION
SEEMS TO BE A BETTER PREDICTOR OF SUBSEQUENT RELAPSE THAN
IG/TCR APPROACH IN CHILDHOOD PH ACUTE LYMPHOBLASTIC LEU-
KEMIA
Muzikova, K.1, Krejcikova, K.1, Sedlacek, P.1, Eva, F.1, Jan, Z.1,
Jan, T.1 1Department of Pediatric Hematology and Oncology, 2nd
Medical School, Charles University Prague, Prague, Czech Republic.
MRD based on leukemia-speciﬁc immunoglobulin (Ig) and
T-cell receptor (TCR) gene rearrangements has become a tool
inﬂuencing clinical decisions in many therapeutic trials for
childhood acute lymphoblastic leukemia (ALL). It has been
repeatedly documented, that positive MRD pre-transplant is
highly predictive for post-transplant relapse of ALL, but we
have failed to document the same value in 14 children with
PhALL which at our unit underwent allogeneic stem cell
transplantation (SCT). The presence of BCR/ABL fusion gene
offers a possibility of the fusion transcript detection - a faster
and cheaper alternative to Ig/TCR-based MRD monitoring. Up
to now, no direct comparison based on a sufﬁcient number of
samples has been done. We have analyzed 350 follow-up sam-
ples from 16 children (aged 4-17 years) with BCR/ABL-positive
ALL by Ig/TCR-based RQ-PCR and by RT-RQ-PCR for
BCR/ABL transcripts. All children expressed m-BCR/ABL
transcript at the time of diagnosis; 3 of 16 children expressed
both m-BCR/ABL and M-BCR/ABL transcripts representing
the p190 and p210 variant of BCR/ABL protein, respectively.
For further analysis we used the higher value of m- and M-BCR/
ABL as the BCR/ABL MRD level. For the comparison with
Ig/TCR-based method, MRD levels in follow-up samples were
related to the expression levels in diagnostic samples, which
were set to 1. In total, 133 (38%) and 127 (36%) samples were
negative and positive by both methods, respectively. The quan-
titative levels differed by more than 1 log in 46 (36%) double-
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